Difficulty: Medium
Average Score: 90%
Practice
A 45-year-old woman has just received a kidney transplant. She is placed on several immunosuppressants to prophylactically prevent her body from rejecting the donor organ. Which of the following immunosuppressants interferes with T-cell activation by inhibition of mTOR?
Correct answer
D
Rationale
In this scenario, the correct answer is D) Sirolimus. Sirolimus interferes with T-cell activation by inhibiting the mammalian target of rapamycin (mTOR) pathway. This inhibition suppresses the immune response, making it an effective immunosuppressant for preventing organ rejection in transplant patients.
Option A) Azathioprine works by interfering with DNA synthesis in actively proliferating cells, but it does not target mTOR or T-cell activation directly.
Option B) Cyclosporine inhibits calcineurin, which is involved in the production of interleukin-2, a key cytokine for T-cell activation. While effective in immunosuppression, it does not act on mTOR like Sirolimus.
Option C) Methotrexate is a folate antagonist that inhibits dihydrofolate reductase, thereby affecting DNA synthesis and cell proliferation. It does not target mTOR or T-cell activation.
Educationally, understanding the mechanisms of action of different immunosuppressants is crucial for healthcare professionals managing transplant patients. Knowing how each drug works helps in selecting the most appropriate therapy for individual patients based on their medical history, risk factors, and potential drug interactions. It also aids in monitoring for side effects and assessing treatment efficacy.
Option A) Azathioprine works by interfering with DNA synthesis in actively proliferating cells, but it does not target mTOR or T-cell activation directly.
Option B) Cyclosporine inhibits calcineurin, which is involved in the production of interleukin-2, a key cytokine for T-cell activation. While effective in immunosuppression, it does not act on mTOR like Sirolimus.
Option C) Methotrexate is a folate antagonist that inhibits dihydrofolate reductase, thereby affecting DNA synthesis and cell proliferation. It does not target mTOR or T-cell activation.
Educationally, understanding the mechanisms of action of different immunosuppressants is crucial for healthcare professionals managing transplant patients. Knowing how each drug works helps in selecting the most appropriate therapy for individual patients based on their medical history, risk factors, and potential drug interactions. It also aids in monitoring for side effects and assessing treatment efficacy.